These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 24535900)
41. Detection of colorectal cancer in urine using DNA methylation analysis. Bach S; Paulis I; Sluiter NR; Tibbesma M; Martin I; van de Wiel MA; Tuynman JB; Bahce I; Kazemier G; Steenbergen RDM Sci Rep; 2021 Jan; 11(1):2363. PubMed ID: 33504902 [TBL] [Abstract][Full Text] [Related]
42. Diagnostic efficacy of SEPT9 and PAX5 gene methylation in gastrointestinal cancer and precancerous lesions. Yan Z; Liu H; Wang K Cell Mol Biol (Noisy-le-grand); 2024 Jul; 70(7):128-133. PubMed ID: 39097885 [TBL] [Abstract][Full Text] [Related]
43. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Powrózek T; Krawczyk P; Kucharczyk T; Milanowski J Med Oncol; 2014 Apr; 31(4):917. PubMed ID: 24633736 [TBL] [Abstract][Full Text] [Related]
44. Detection of colorectal cancer by DNA methylation biomarker SEPT9: past, present and future. Li Y; Song L; Gong Y; He B Biomark Med; 2014; 8(5):755-69. PubMed ID: 25123042 [TBL] [Abstract][Full Text] [Related]
45. Methylation of FBN1, SPG20, ITF2, RUNX3, SNCA, MLH1, and SEPT9 genes in circulating cell-free DNA as biomarkers of colorectal cancer. Alizadeh-Sedigh M; Fazeli MS; Mahmoodzadeh H; Sharif SB; Teimoori-Toolabi L Cancer Biomark; 2022; 34(2):221-250. PubMed ID: 34957998 [TBL] [Abstract][Full Text] [Related]
46. Progress on the clinical application of the SEPT9 gene methylation assay in the past 5 years. Song L; Li Y Biomark Med; 2017 May; 11(6):415-418. PubMed ID: 28617104 [No Abstract] [Full Text] [Related]
47. Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance. Jiao X; Zhang S; Jiao J; Zhang T; Qu W; Muloye GM; Kong B; Zhang Q; Cui B Clin Epigenetics; 2019 Aug; 11(1):120. PubMed ID: 31426855 [TBL] [Abstract][Full Text] [Related]
48. A DNA methylation panel for high performance detection of colorectal cancer. Jamialahmadi K; Azghandi M; Javadmanesh A; Zardadi M; Shams Davodly E; Kerachian MA Cancer Genet; 2021 Apr; 252-253():64-72. PubMed ID: 33387936 [TBL] [Abstract][Full Text] [Related]
49. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. deVos T; Tetzner R; Model F; Weiss G; Schuster M; Distler J; Steiger KV; Grützmann R; Pilarsky C; Habermann JK; Fleshner PR; Oubre BM; Day R; Sledziewski AZ; Lofton-Day C Clin Chem; 2009 Jul; 55(7):1337-46. PubMed ID: 19406918 [TBL] [Abstract][Full Text] [Related]
50. Discovery and Validation of Hypermethylated Markers for Colorectal Cancer. Wei J; Li G; Dang S; Zhou Y; Zeng K; Liu M Dis Markers; 2016; 2016():2192853. PubMed ID: 27493446 [TBL] [Abstract][Full Text] [Related]
51. Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer. Danese E; Minicozzi AM; Benati M; Montagnana M; Paviati E; Salvagno GL; Lima-Oliveira G; Gusella M; Pasini F; Lippi G; Guidi GC PLoS One; 2015; 10(5):e0126417. PubMed ID: 25946211 [TBL] [Abstract][Full Text] [Related]
52. A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway. Freitas M; Ferreira F; Carvalho S; Silva F; Lopes P; Antunes L; Salta S; Diniz F; Santos LL; Videira JF; Henrique R; Jerónimo C J Transl Med; 2018 Feb; 16(1):45. PubMed ID: 29486770 [TBL] [Abstract][Full Text] [Related]
53. Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients. Matsui S; Kagara N; Mishima C; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S Oncol Rep; 2016 Oct; 36(4):2225-35. PubMed ID: 27499429 [TBL] [Abstract][Full Text] [Related]
55. Multiple Biomarker-Combined Screening for Colorectal Cancer Based on Bisulfate Conversion-Free Detection of Fecal DNA Methylation. Liu C; Xu L; Li W; Jie M; Xue W; Yu W Biomed Res Int; 2021; 2021():1479748. PubMed ID: 34621892 [TBL] [Abstract][Full Text] [Related]
56. Predictive nomogram of the clinical outcomes of colorectal cancer based on methylated SEPT9 and intratumoral IL-10 Sun J; Shi S; Sun C; Wang J; Yang X; Yang Z; Xu J; Zhang S J Transl Med; 2024 Sep; 22(1):861. PubMed ID: 39334238 [TBL] [Abstract][Full Text] [Related]
57. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer. Fu B; Yan P; Zhang S; Lu Y; Pan L; Tang W; Chen S; Chen S; Zhang A; Liu W Dis Markers; 2018; 2018():6437104. PubMed ID: 29849824 [TBL] [Abstract][Full Text] [Related]
59. A novel dual-target Septin9 methylation assay for improved detection of early-stage colorectal cancer and high-grade intraepithelial neoplasia. Wu Y; Tong Y; Zhang H; Li Y; Zhu X; Li M; Qiu L; Liu W; Mei S; Mao Y; Cao Y; Su C; Yu W; Wang J; Wang T; Zhu Z; Yu DH BMC Cancer; 2024 Jul; 24(1):916. PubMed ID: 39080571 [TBL] [Abstract][Full Text] [Related]
60. Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as noninvasive biomarkers for the early detection of colorectal cancer and advanced adenomas. Gallardo-Gómez M; Rodríguez-Girondo M; Planell N; Moran S; Bujanda L; Etxart A; Castells A; Balaguer F; Jover R; Esteller M; Cubiella J; Gómez-Cabrero D; De Chiara L Clin Epigenetics; 2023 Oct; 15(1):157. PubMed ID: 37794510 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]